![](/img/cover-not-exists.png)
CP2 ESTIMATING THE SURVIVAL AND COST IMPACT OF INTRODUCING FIRST-LINE ALECTINIB AND OSIMERTINIB FOR PATIENTS WITH ADVANCED NSCLC: AN ITEN MODEL ASSESSMENT
Moldaver, D., Zhou, A., Grima, D., Hurry, M.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.025
Date:
May, 2019
File:
PDF, 655 KB
english, 2019